Yesterday, March 8, 2016, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $567.44 to $9,409,592.36.

Highlighted Stocks Traded by Insiders:

Motorcar Parts of America (MPAA) - FREE Research Report

Selwyn Joffe, who is President, CEO & Chairman at Motorcar Parts of America, sold 4,597 shares at $38.00 on March 8, 2016. Following this transaction, the President, CEO & Chairman owned 114,942 shares meaning that the stake was reduced by 3.85% with the 4,597-share transaction.

The shares most recently traded at $36.63, down $1.37, or 3.74% since the insider transaction. Historical insider transactions for Motorcar Parts of America go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 4,071
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 4,071
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 4,071

The average volume for Motorcar Parts of America has been 196,300 shares per day over the past 30 days. Motorcar Parts of America has a market cap of $677.4 million and is part of the consumer goods sector and automotive industry. Shares are up 7.34% year-to-date as of the close of trading on Tuesday.

Motorcar Parts of America, Inc. remanufactures, manufactures, and distributes automotive aftermarket parts. The company has a P/E ratio of 61.6. Currently, there are 3 analysts who rate Motorcar Parts of America a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MPAA - FREE

TheStreet Quant Ratings

rates Motorcar Parts of America as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Motorcar Parts of America Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LendingTree (TREE) - FREE Research Report

Patel Nikul, who is Chief Operating Officer at LendingTree, sold 4,000 shares at $89.35 on March 8, 2016. Following this transaction, the Chief Operating Officer owned 33,000 shares meaning that the stake was reduced by 10.81% with the 4,000-share transaction.

The shares most recently traded at $84.02, down $5.33, or 6.34% since the insider transaction. Historical insider transactions for LendingTree go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 9,000
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 9,000
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 136,000

The average volume for LendingTree has been 847,800 shares per day over the past 30 days. LendingTree has a market cap of $1.1 billion and is part of the financial sector and real estate industry. Shares are down 4.58% year-to-date as of the close of trading on Tuesday.

LendingTree, Inc., through its subsidiaries, operates an online loan marketplace for consumers seeking an array of loan types and other credit-based offerings in the United States. The company operates in four segments: Lending, Auto, Education, and Home Services. The company has a P/E ratio of 22.0. Currently, there are 5 analysts who rate LendingTree a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TREE - FREE

TheStreet Quant Ratings

rates LendingTree as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

LendingTree Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

US Physical Therapy (USPH) - FREE Research Report

Mcafee Lawrance W, who is Chief Financial Officer at US Physical Therapy, sold 5,000 shares at $52.74 on March 8, 2016. Following this transaction, the Chief Financial Officer owned 45,212 shares meaning that the stake was reduced by 9.96% with the 5,000-share transaction.

The shares most recently traded at $50.95, down $1.79, or 3.51% since the insider transaction. Historical insider transactions for US Physical Therapy go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 4,500
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 8,500
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 41,799

The average volume for US Physical Therapy has been 84,800 shares per day over the past 30 days. US Physical Therapy has a market cap of $637.3 million and is part of the health care sector and health services industry. Shares are down 4.36% year-to-date as of the close of trading on Tuesday.

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics in the United States. The stock currently has a dividend yield of 1.33%. The company has a P/E ratio of 28.5. Currently, there is 1 analyst who rates US Physical Therapy a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USPH - FREE

TheStreet Quant Ratings

rates US Physical Therapy as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

US Physical Therapy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.